3 citations
,
January 2024 in “Annals of Dermatology” The criteria help doctors diagnose and treat alopecia areata more effectively.
January 2024 in “Annals of Dermatology” Current treatments for Alopecia Areata don't fully meet patients' needs, indicating a need for better therapies.
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
6 citations
,
January 2023 in “Annals of Dermatology” The guidelines offer updated treatment recommendations for alopecia areata in Korea using topical and device-based methods.
1 citations
,
December 2014 Some drugs have gained approval for new uses, while others like tricyclic antidepressants and aspirin show promise but aren't yet approved for these uses.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib works better in adolescents than adults for treating severe alopecia areata.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
July 2022 in “Research Square (Research Square)” Lower PPARγ levels and specific gene variations are linked to more severe Frontal Fibrosing Alopecia.
29 citations
,
July 2010 in “Journal of Cutaneous Medicine and Surgery” Treatments for Frontal Fibrosing Alopecia have not been proven effective.
March 2016 in “West Indian medical journal” There is no significant link between alopecia areata and the PON1 enzyme polymorphisms studied.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
1 citations
,
January 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors effectively treat skin conditions and topical forms are safer.
58 citations
,
July 2007 in “Clinics in Dermatology” Tattooing helps treat skin conditions, reconstruct nipple-areola, mark radiation fields, and locate lesions.
37 citations
,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
22 citations
,
May 2011 in “American Journal of Clinical Dermatology” Recognizing and managing skin-related psychiatric disorders in children is crucial for effective treatment.
4 citations
,
May 2025 in “Dermatology and Therapy” Baricitinib effectively improves symptoms of atopic dermatitis and alopecia areata with few side effects.
1 citations
,
September 2024 in “IP Indian Journal of Clinical and Experimental Dermatology” Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.
March 2026 in “American Journal of Clinical Dermatology” Cancer survivors need better skin care to improve their quality of life.
April 2024 in “Frontiers in medicine” Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
January 2021 in “Online Publication Service of Würzburg University (Würzburg University)” Diphenylcyclopropenon treatment for Alopecia areata is effective and safe, improving patients' quality of life.
December 2017 in “Springer eBooks” Treat pediatric skin issues with accurate diagnosis, multidisciplinary team, and various treatment options.
7 citations
,
November 2018 in “Journal of the American Academy of Dermatology” White hairs often regrow in alopecia areata patches.
5 citations
,
June 2012 in “QJM: An International Journal of Medicine” The lecture concluded that drugs for human enhancement are here to stay and called for their responsible development and fair access.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
September 2025 in “Value in Health” January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
17 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.